10:57 AM
Jan 09, 2019
 |  BC Extra  |  Company News

China’s Junshi prices domestic anti-PD-1 mAb at deep discount

Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877) priced its domestically developed anti-PD-1 mAb Tuoyi toripalimab at a deep discount compared with the China price of Keytruda pembrolizumab from Merck...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >